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Pao-Yen Lin15,16, Yu-Shian Cheng4* & Ming-Kung Wu15*
Attention-deficit/hyperactivity disorder (ADHD) frequently co-occurs with intellectual disability in 
children, and may further compromise learning. Methylphenidate is a first-line treatment for ADHD, 
however no previous meta-analysis has evaluated its overall efficacy for ADHD in children with comorbid 
intellectual disability (ID) or borderline intellectual functioning. The PubMed/MEDLINE, Cochrane 
CENTRAL and ScienceDirect databases were systematically searched from inception through 2018/7/15 
for clinical studies that investigated the effects of methylphenidate in children with ADHD and ID. 
A random-effects model meta-analysis was used for data synthesis. Eight studies (average Jadad 
score = 2.5) enrolling 242 participants receiving methylphenidate and 181 participants receiving placebo 
were included. The meta-analysis showed that methylphenidate led to a significant improvement in 
ADHD symptoms relative to placebo (Hedges’ g = 0.878, p < 0.001). Meta-regression analysis pointed 
to an association between the dose of methylphenidate and overall improvement in ADHD severity 
(slope = 1.334, p < 0.001). Finally, there was no significant difference in drop-out rate [odds ratio 
(OR) = 1.679, p = 0.260] or rate of treatment discontinuation due to adverse events (OR = 4.815, p = 0.053) 
between subjects receiving methylphenidate and those taking placebos. Our study suggests that 
methylphenidate retains its efficacy in children with ADHD and borderline intellectual functioning or ID.
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Attention-deficit/hyperactivity disorder (ADHD) can present with symptoms encompassing inattentive, hyper-
activity and impulsivity domains, and is associated with significant psychosocial and academic dysfunctions1. 
ADHD is the most common neurobehavioral disorder amongst children and adolescents2. In addition, children 
with probable ADHD have been reported to have a 16-point decrease in IQ compared to those without ADHD3. 
These findings highlight an association between ADHD and subaverage intelligence4. Both pharmacological and 
non-pharmacological treatments have shown efficacy for the management of ADHD2,5.
Among pharmacological treatments, methylphenidate has been recommended as a first-line agent for 
ADHD6. It primarily acts through the inhibition of presynaptic dopamine and to a lesser extent norepinephrine 
transporter, thereby increasing the concentration of monoamines in the synaptic cleft7. Adjusting the dose on an 
individual basis has been reported to be crucial for optimizing behavioral improvement8. In addition, the bene-
ficial effects of methylphenidate for the management of ADHD have been well documented in review articles9, 
pairwise meta-analyses10, and network meta-analyses11.
Despite the possible association between ADHD and intellectual disability (ID), most treatment trials for ADHD 
have excluded children with ID or borderline intellectual functioning, partly because children with ID often have 
coexisting medical problems and are also less likely to self-report adverse events4. The reliability of data derived from 
previous studies on the therapeutic effectiveness of methylphenidate in children with ID or borderline intellectual 
functioning is further hampered by crossover designs, short trial durations, differences in dosing regimens, and 
small sample sizes4. Whilst some studies have demonstrated a poorer therapeutic response in children with ID or 
borderline intellectual functioning compared to those without12, other studies have not found a significant difference 
in efficacy between the two groups4. In addition, a dose-dependent therapeutic effect was reported in one study13 
but not in others14,15. Furthermore, one report failed to demonstrate an overall therapeutic effect for methylpheni-
date16 in this patient population. There are also inconsistencies in the therapeutic effects of methylphenidate on the 
conduct subscale. While some studies have demonstrated positive outcomes17,18, others have failed to show any ben-
eficial impact14,15. Moreover, most studies have failed to show that methylphenidate significantly improved cognitive 
performance as measured by a continuous performance test (CPT)14,16,18. A recent systematic review of different 
RCTs reported that people with ID had a lower (40–50%) response rate to methylphenidate than those without ID19. 
However, the authors did not conduct meta-analysis to reinforce their conclusion. Due to these gaps in the literature, 
the aim of this systematic review and meta-analysis of randomized controlled trials was to assess the therapeutic 
effects of methylphenidate in children with ADHD and co-occurring ID or borderline intellectual functioning.
Materials and Methods
Guidelines and protocol. This systematic review and meta-analysis was conducted according to the guide-
lines presented in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement20 
(Supplementary Table 1, available online). An a priori defined but unpublished protocol (available upon request 
to the authors) that was approved by the Institutional Review Board of Tri-Service General Hospital (TSGHIRB: 
B-105-12) was followed.
Search strategy and identification of eligible studies. Two investigators (YS Cheng and CK Sun) 
independently searched the PubMed/MEDLINE, Cochrane Library and Science Direct electronic databases from 
inception to 2018/7/15, using the following keywords: (Stimulants or methylphenidate) and (mental retardation 
or intellectual disability or development delay or mental handicap or borderline intellectual functioning). We 
limited the results to clinical trials. In addition, the ClinicalTrials.gov database was searched using the following 
keywords: (ADHD and methylphenidate). This search strategy was augmented through a hand search of reference 
lists for eligible articles as well as relevant clinical guidelines and review articles2,7,10,21.
Two authors (YS Cheng and CK Sun) screened the titles and abstracts of retrieved references for eligibility. 
A list of potentially eligible studies was constructed by consensus, after which full-text examinations were con-
ducted. A third reviewer (PT Tseng) was consulted if any inconsistencies arose.
Eligibility criteria. The inclusion criteria were as follows: (1) peer-reviewed articles investigating the efficacy 
of methylphenidate on behavioral symptoms in children and adolescents with borderline intellectual functioning 
or ID symptoms who were experiencing behavioral problems related to ADHD according to the diagnostic crite-
ria in the International Statistical Classification of Diseases and Related Health Problems (ICD), in the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) or other standardized rating scales; and (2) articles that were 
randomized placebo-controlled trials conducted in humans. No language restrictions were applied.
The exclusion criteria were as follows: (1) animal studies; (2) trials not related to the treatment effect of methyl-
phenidate on behavioral symptoms related to ADHD; and (3) studies without a placebo group (i.e., head-to-head 
trials).
Methodological quality appraisal. The methodological quality of the included studies was evaluated using 
the Jadad scale22. Jadad scores were calculated for each included study and encompassed three aspects of study quality, 
namely, randomization, blindness, and attrition rates. Scores ranged from zero (poor quality) to five (high quality).
Outcome assessment. For comprehensive evaluation, we studied the association between changes in clin-
ical symptoms of ADHD and use of methylphenidate at two stages. Initially, we evaluated the change in overall 
severity of ADHD symptoms, which was defined as the primary outcome. At the second stage, to provide more 
information for clinicians, we assessed the changes in severity of ADHD symptoms on different subscales, which 
were defined as the secondary outcomes.
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The secondary outcomes of interest included any rating scales that evaluated the three main categories of behavioral 
problems in ADHD, including conduct behavior, hyperactivity and inattentive symptoms. We also evaluated differ-
ences in CPT results between groups treated with placebo and those treated with methylphenidate. Finally, tolerability 
as assessed by the drop-out rate and the rate of treatment discontinuation due to adverse effects was also analyzed.
Data extraction and management. Two independent authors extracted data from the eligible studies 
into a database of pre-determined variables of interest. The extracted variables included: changes in the severity 
of ADHD symptoms, mean age (years), female proportion, mean body mass index (BMI), methylphenidate treat-
ment duration (weeks), and methylphenidate dosage (mg/kg/day).
When data were not available in the articles, we tried to contact the corresponding authors by email to request 
additional data on at least two different occasions one week apart.
Statistical analysis. Due to the presumed heterogeneity among the included studies, data were ana-
lyzed using random-effects meta-analysis models rather than fixed effects models23 on the Comprehensive 
Meta-Analysis software version 3 platform (Biostat, Englewood, NJ). Effect sizes (ESs) of changes in ADHD 
symptoms between groups were analyzed using Hedges’ g and 95% confidence intervals (95% CIs). For the sec-
ondary outcomes, because all the input-data were based on the same rating scale, we further calculated the mean 
differences (MDs), which could provide clearer and more relevant information for clinicians. In the situations of 
dichotomous outcome, the ESs were analyzed using odds ratio (OR) and 95% CIs.
Heterogeneity was evaluated using the Q statistic24, and the I2 statistic was used to evaluate the proportion of 
variation25. We examined publication bias by visually inspecting funnel plots when less than ten datasets were 
available26, while Egger’s regression test was used when ten or more independent datasets were available23. We 
performed the Duval and Tweedie trim and fill test to adjust ESs when evidence of publication bias was found27. 
Sensitivity analysis where one study at a time was excluded from the analysis was performed to verify whether an 
outlier could be biasing our ES estimates28.
To evaluate potential sources of heterogeneity and confounding effects, we performed meta-regression and 
subgroup meta-analyses. Specifically, when there were at least five datasets, we conducted the meta-regression 
procedure using the unrestricted maximum likelihood method. Regarding subgroup meta-analysis, we focused 
on the studies that included different dosages of methylphenidate. Specifically, we subdivided the included stud-
ies according to the mean dosage of methylphenidate with the cut-off point set at 0.6 mg/day (i.e., the low-dose 
subgroup ≤ 0.6 mg/day and the high-dose subgroup > 0.6 mg/day). This cut-off point was previously used in a 
meta-analysis in Cochrane Systematic Reviews29. We performed subgroup analysis when data from at least three 
independent studies were provided29. In addition, we used interaction tests to evaluate differences in ESs between 
the subgroups30. Statistical significance was set at a two-tailed alpha level of 0.05.
Results
Study selection. The PRISMA flowchart used to select the studies in this systematic review is shown in 
Fig. 1. After excluding duplicates, 30 full-text articles were assessed for eligibility. Among them, 22 were excluded 
(see Supplementary Table 2 for the reasons why these studies were excluded). Therefore, eight articles were eligi-
ble for the current meta-analysis (Table 1)4,13–18,31.
Among the eight eligible articles, 242 subjects received methylphenidate (mean age = 9.17 years, mean 
female proportion = 26.9%, median treatment duration = 2.5 weeks) and 181 subjects receiving placebo (mean 
age = 9.42 years, mean female proportion = 26.9%). Of the eight studies, five recruited subjects diagnosed accord-
ing to the DSM-III-R13–15,18,31, one according to the ICD-104, one according to the DSM-III17, and one according 
to the Conners’ Parent or Teacher Rating Scale16.
Figure 1. Flowchart of literature retrieval and appraisal for the current systematic review and meta-analysis.
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With regards to ADHD symptom evaluation, all eight articles4,13–18,31 evaluated symptoms using the Conners’ 
Teacher Rating Scale (CTRS)32, three4,17,31 with the Aberrant Behavior Checklist (ABC)33, and only two4,31 with 
Conners’ Parents Rating Scale (CPRS)34. Three articles also evaluated changes in CPT scores14,16,18.
Methodological quality of the included studies. Among the eight studies, the average Jadad score was 
2.5 with a standard deviation (SD) of 1.07 (Supplementary Table 3).
Primary outcome: treatment effect on ADHD symptoms as assessed by changes in severity. 
Primary outcome: overall severity. The meta-analysis of the eight studies with twelve datasets evaluating the 
changes in overall ADHD severity4,13–18,31, showed that the subjects receiving methylphenidate had better improve-
ments in overall ADHD severity than those receiving placebo (k = 12, Hedges’ g = 0.878, 95% CI = 0.612 to 1.143, 
p < 0.001) (Fig. 2(a)) without significant heterogeneity (Q value = 19.027, df = 11, I2 = 42.188%, p = 0.061) but with 
significant publication bias via Egger’s regression test (t = 3.093, df = 10, p = 0.011). The adjusted ESs by Duval and 
Tweedie’s trim and fill test remained statistically significant (adjusted Hedges’ g = 0.641, 95% CI = 0.338 to 0.943).
Sensitivity analysis. The sensitivity test where one study at a time was excluded from the analysis revealed that 
the significant results of the meta-analysis did not change after the removal of any one of the included studies. 
Therefore, the significance of the results was not due to any outliers among the included studies.
Meta-regression. Meta-regression suggested a significant positive association between changes in overall ADHD 
severity and methylphenidate dosage (k = 11, slope = 1.334, p < 0.001) with no significant associations between 
changes in overall ADHD severity and mean age (p = 0.366), female proportion (p = 0.112), mean IQ (p = 0.119), 
or treatment duration (p = 0.465).
Study (year) Diagnosis Criteria Design Comparison N
Duration 
(weeks) Outcome
Mean age 
(years) Female Country
Simonoff E
(2013)
1. Hyperkinetic 
disorder
2. IQ = 30–69
ICD 10 RCT
1. MPH-IR 0.5–1.5 mg/
kg/day (adjusted by 
clinical response)
61
16
Teacher:
Conner ADHD index (+)
Connerhyperactivity (+)
ABC hyperactivity (+)
Parents:
Conner ADHD index (+)
Conner hyperactivity (+)
ABC hyperactivity (+)
10.83 26%
UK
2. Placebo 61 11.5 34%
Handen BL 
(1999)
1. ADHD
2. IQ = 40–78 DSM-III-R
Double-
blind
Crossover
1. MPH 0.6 mg/kg/day 11
1
Teacher:
Conner Hyperactivity index (+)
Conner Hyperactivity subscale (+)
Conner Conduct subscale (−)
Conner Inattention subscale (+)
4.9 18% USA2. MPH 1.2 mg/kg/day 11
3. Placebo 11
Aman MG
(1997)
1. ADHD
2. IQ < 85 DSM-III-R
Double-
blind
Crossover
1. MPH 0.4 mg/kg/day 30
2
Teacher:
Conner Abbreviated (-)
Conner Hyperactivity subscale (+)
Conner Conduct subscale
Conner Inattention subscale
ABC hyperactivity (+)
Parents:
Conner Abbreviated (-)
ABC hyperactivity (-)
7.7 26.7% USA
2. Fenfluramine 1–2 mg/
kg/day 30
3. Placebo 30
Aman MG
(1993)
1. ADHD
2. IQ ≦ 78 DSM-III-R
Double-
blind
Crossover
1. MPH 0.4 mg/kg/day 28
4
Teacher:
Conner Hyperactivity subscale (+)
Conner Conduct subscale (+)
Conner Inattention subscale (+)
ABC hyperactivity (+)
Parents:
Conner Abbreviated (-)
ABC hyperactivity (+)
8.8 28.6% USA
2. Fenfluramine 1.5 mg/
kg/day 28
3. Placebo 28
Handen BL 
(1992)
1. ADHD
2. IQ < 80 DSM-III-R
Double-
blind
Crossover
1. MPH 0.6 mg/kg/day 14
3
Teacher:
Conner Hyperactivity index (+)
Conner Hyperactivity subscale (+)
Conner Conduct subscale (−)
Conner Inattention subscale (+)
9.1 28.6% USA2. MPH 1.2 mg/kg/day 14
3. Placebo 14
Handen BL 
(1990)
1. ADHD
2. IQ < 80 DSM-III-R
Double-
blind
Crossover
1. MPH 0.6 mg/kg/day 12
3
Teacher:
Conner Hyperactivity index (+)
Conner Hyperactivity subscale (+)
Conner Conduct subscale (+)
Conner Inattention subscale (−/+)
6–9 8.3% USA2. MPH 1.2 mg/kg/day 12
3. Placebo 12
Hagerman RJ 
(1988)
1. Attention 
problems
2. Fragile X 
syndrome
(IQ ≦ 77)
Conner’s 
rating scale
Double-
blind
Crossover
1. MPH 0.6 mg/kg/day 15
1
Teacher:
Conner Abbreviated (−)
Parents:
Conner Abbreviated (-)
7.9 13% USA2. Dextroamphetamin 0.2 mg/kg/day 15
3. Placebo 15
Varley CK
(1982)
1. Attention 
problems
2. IQ ≦ 77
DSM-III
Double-
blind
Crossover
1. MPH 0.3 mg/kg/day 10
1
Teacher:
Conner Hyperactivity index (+/−)
Parents:
Conner Hyperactivity index (+/−)
11.33 30% USA2. MPH 0.6 mg/kg/day 10
3. Placebo 10
Table 1. Summary of characteristics of studies in the current meta-analysis.
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Secondary outcomes: treatment effect on ADHD symptoms as assessed by changes in sub-
scales of different dimensions of CTRS. Secondary outcome: conduct problem severity as assessed 
by CTRS-conduct. When focusing on the five studies14,15,17,18,31 with eight datasets evaluating changes in 
CTRS-conduct, the meta-analysis showed that the subjects receiving methylphenidate had better improve-
ments in CTRS-conduct severity than those receiving placebo (k = 8, Hedges’ g = 0.853, 95% CI = 0.516 to 1.189, 
p < 0.001; MDs = 0.816) (Fig. 3(a)) without significant heterogeneity (Q value = 12.089, df = 7, I2 = 42.098%, 
p = 0.098) or publication bias via inspection of the funnel plot (Fig. 4(a)).
Secondary outcome: hyperactive severity as assessed by CTRS-hyperactive. An investigation into the six stud-
ies4,14,15,17,18,31 with nine datasets evaluating changes in CTRS-hyperactive demonstrated that the subjects receiv-
ing methylphenidate had better improvements in CTRS-hyperactive severity compared to those receiving placebo 
(k = 9, Hedges’ g = 1.068, 95% CI = 0.741 to 1.395, p < 0.001; MDs = 1.976) (Fig. 3(b)) with significant hetero-
geneity (Q value = 16.687, df = 8, I2 = 52.058%, p = 0.034) and significant publication bias via inspection of the 
funnel plot (Fig. 4(b)). The adjusted ESs by Duval and Tweedie’s trim and fill test remained statistically significant 
(adjusted Hedges’ g = 0.694, 95% CI = 0.348 to 1.041).
Secondary outcome: inattention severity as assessed by CTRS-inattention. Considering the five studies14,15,17,18,31 
with eight datasets evaluating changes in CTRS-inattention, the meta-analysis showed that the subjects receiving 
methylphenidate had better improvements in CTRS-inattention severity than those receiving placebo (k = 8, 
Hedges’ g = 0.834, 95% CI = 0.587 to 1.080, p < 0.001; MDs = 0.742) (Fig. 3(c)) without significant heterogeneity 
(Q value = 3.221, df = 7, I2 < 0.001%, p = 0.864) but significant publication bias via inspection of the funnel plot 
(Fig. 4(c)). The adjusted ESs by Duval and Tweedie’s trim and fill test remained statistically significant (adjusted 
Hedges’ g = 0.717, 95% CI = 0.500 to 0.934).
Subgroup meta-analysis: treatment effect on ADHD symptoms with different methylphenidate dosages. Subgroup 
meta-analysis showed that the subjects receiving methylphenidate had better improvements in overall ADHD 
severity than those receiving placebo both in the low-dose (k = 8, Hedges’ g = 0.694, 95% CI = 0.448 to 0.940, 
p < 0.001) and high-dose (k = 3, Hedges’ g = 1.638, 95% CI = 1.123 to 2.153, p < 0.001) subgroups13–18,31. 
Furthermore, the ESs were significantly higher in the high-dose subgroup than those in the low-dose subgroup 
by the interaction test (p = 0.001)14,15,18.
Secondary outcome: treatment effect on continuous performance as assessed by changes in CPT. When focus-
ing on the three studies14,16,18 that investigated differences in CPT results between placebo and methylphenidate 
treatment groups, the meta-analysis showed that the subjects receiving methylphenidate had better improve-
ments in CPT results than those receiving placebo (k = 5, Hedges’ g = 0.558, 95% CI = 0.214 to 0.902, p = 0.001; 
MDs = 11.955) (Fig. 3(d)) without significant heterogeneity (Q value = 4.141, df = 4, I2 = 3.405%, p = 0.387) but 
significant publication bias via inspection of the funnel plot (Fig. 4(d)). The adjusted ESs by Duval and Tweedie’s 
trim and fill test remained statistically significant (adjusted Hedges’ g = 0.368, 95% CI = 0.009 to 0.727).
Secondary outcome: tolerability assessed by drop-out rate and rate of treatment discontinuation due to adverse 
events. The current meta-analysis showed no significant difference in drop-out rate between subjects receiving 
methylphenidate and those taking placebos (k = 4, OR = 1.679, 95% CI = 0.681 to 4.138, p = 0.260) (Fig. 2(b)). 
Forest plot demonstrated no significant heterogeneity (Q value = 0.460, df = 3, I2 < 0.001%, p = 0.928) or signifi-
cant publication bias (Fig. 4(e)).
Similarly, there was no significant difference in the rate of treatment discontinuation due to adverse events between 
subjects treated with methylphenidate and those receiving placebos (k = 4, OR = 4.815, 95% CI = 0.981 to 23.628, 
p = 0.053) (Fig. 2(b)). Despite the lack of significant heterogeneity (Q value = 0.579, df = 3, I2 < 0.001%, p = 0.901), sig-
nificant publication bias was noted via inspection of the funnel plot (Fig. 4(f)). The adjusted ESs by Duval and Tweedie’s 
trim and fill test showed significantly higher rate of treatment discontinuation due to adverse events in subjects receiv-
ing methylphenidate than those taking placebos (adjusted OR = 5.531, 95% CI = 1.326 to 23.069).
Discussion
To the best of our knowledge, this is the first meta-analysis to address the treatment effect of methylphenidate 
on children with ADHD and ID or borderline intellectual functioning. Our meta-analysis suggested that chil-
dren with borderline intellectual functioning or ID receiving methylphenidate experienced better improvements 
than those receiving placebo in both overall ADHD severity (p < 0.001) and ADHD-specific symptoms, includ-
ing CTRS-conduct (p < 0.001), CTRS-hyperactivity (p < 0.001), CTRS-inattention (p < 0.001) and CPT results 
(p = 0.001). Furthermore, our meta-regression analysis also showed that the efficacy of methylphenidate was 
related to its dosage. Finally, there was no significant difference in drop-out rate or rate of treatment discontinua-
tion due to adverse events between subjects receiving methylphenidate and those taking placebos.
The main findings of the current meta-analysis were the beneficial effects of methylphenidate on the symp-
toms of ADHD, both in primary outcome (overall disease severity) and secondary outcomes (hyperactivity, 
conduct, inattention and CPT results) in children with ADHD and ID or borderline intellectual functioning. 
These findings are similar to those in previous meta-analyses conducted in children with ADHD and a nor-
mal IQ10,35. Therefore, our findings further support the potentially beneficial effect of methylphenidate against 
ADHD symptoms, which has not been well studied previously and has shown controversial results in this study 
population14,15,17,18.
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Our study demonstrated that the efficacy of methylphenidate treatment increased with an increased dosage, 
as shown in our meta-regression analysis (slope = 1.334, p < 0.001) and subgroup analyses (Hedges’ g = 0.694 in 
the low-dose subgroup, Hedges’ g = 1.638 in the high-dose subgroup, interaction test between the two subgroups: 
Figure 2. Forest plot of (a) primary outcome of the current meta-analysis, showing significant improvements 
in the overall severity of attention-deficit/hyperactivity disorder (ADHD) after methylphenidate treatment 
compared to that in placebo groups (Hedges’ g = 0.878, 95% CI = 0.612 to 1.143, p < 0.001), and (b) 
secondary outcome of the current meta-analysis, indicating insignificant difference in safety profile between 
methylphenidate and placebo treatments as assessed by drop-out rate (odds ratio = 1.679, 95% CI = 0.681 
to 4.138, p = 0.260) and rate of treatment discontinuation due to adverse events (odds ratio = 4.815, 95% 
CI = 0.981 to 23.628, p = 0.053).
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p = 0.001). These findings may prompt the development of new strategies in clinical practice. Currently, the 
most common strategy for children taking methylphenidate in clinical practice is “dose optimization”, which 
is defined as “start with a low dose and titrate gradually upward to an optimal low-dose”36. The different treat-
ment effect of methylphenidate found in the current meta-analysis may be partially supported by a previous 
meta-analysis conducted in children with ADHD and a normal IQ10. In that meta-analysis, although the overall 
results of the meta-analysis were based on both randomized clinical trials and cross-over trials and did not find 
any difference in treatment efficacy between low-dose (≦0.6 mg per day) or high-dose (>0.6 mg per day) treat-
ment, the treatment effects became significantly higher in the high-dose group if they only focused on trials 
with a cross-over design10. This interesting finding may provide some evidence for individual variations in dose 
response. Moreover, it has been shown that certain individuals may respond to a higher dose of methylphenidate, 
but that substantial inter-subject variability may exist in response to methylphenidate dosage37. However, given 
the potentially higher incidence of adverse events in patients with subaverage IQ4, further large-scale randomized 
controlled trials about the potential adverse events in children with ADHD and ID or borderline intellectual 
function are warranted.
Finally, with regards to the safety and tolerability of methylphenidate in children with ADHD and ID or bor-
derline intellectual functioning, we did not find significant difference in drop-out rate (OR = 1.679, p = 0.260) 
or rate of treatment discontinuation due to adverse events (OR = 4.815, p = 0.053) between subjects treated with 
methylphenidate and those receiving placebos. Moreover, most studies reported that methylphenidate was well 
tolerated without reports of severe adverse events (Supplementary Table 4). Overall, methylphenidate seemed 
well tolerated in the studied populations.
Limitations. There are several limitations to the present meta-analysis that should be addressed prior to its 
application in clinical practice. First, the heterogeneous nature of the included studies should be noted, including 
the wide range of dosages of methylphenidate (0.6 to 1.2 mg/kg/day), wide range of methylphenidate treatment 
duration (1–16 weeks), short treatment duration in most of the included studies (seven of the eight studies had 
a treatment duration of between 1 and 4 weeks), male predominance (73.1%), and mainly Caucasian ethnicity. 
In addition, most of the included studies were cross-over studies with quality being ranked as poor in five of the 
eight studies. Second, the number of the included studies and the overall sample sizes were relatively small. Third, 
only one of the included studies was published in the last decade.
Figure 3. Forest plot of secondary outcomes of the current meta-analysis, demonstrating significant 
improvements in (a) CTRS-conduct subscales (Hedges’ g = 0.853, 95% CI = 0.516 to 1.189, p < 0.001), (b) 
CTRS-hyperactive subscales (Hedges’ g = 1.068, 95% CI = 0.741 to 1.395, p < 0.001), (c) CTRS-inattention 
subscales (Hedges’ g = 0.834, 95% CI = 0.587 to 1.080, p < 0.001), and (d) CPT scores (Hedges’ g = 0.558, 95% 
CI = 0.214 to 0.902, p = 0.001) after methylphenidate treatment compared to the placebo groups. Abbreviations: 
ADHD: Attention deficit hyperactivity disorder; AE: adverse event; CI: confidence interval; CPT: continuous 
performance test; CTRS: Conners’ Teacher Rating Scale; MA: meta-analysis.
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Conclusions
The current meta-analysis provides evidence in support of a significant dose-dependent beneficial effect of meth-
ylphenidate on overall ADHD severity, conduct, hyperactivity, and inattentive symptoms in children with ADHD 
and ID or borderline intellectual functioning. Further large-scale well-designed randomized clinical trials investi-
gating the treatment efficacy and tolerability of methylphenidate in this population are warranted.
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